ArticleJournal of clinical medicine2021
Evaluation of Oxidative Stress Status in Familial Hypercholesterolemia.
Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Evaluation of High-Density Lipoprotein Capacity to Acquire Free Cholesterol From Triglyceride-Rich Lipoproteins During Reverse Remnant-Cholesterol Transport in Familial Hypercholesterolemia.Endocrinology, diabetes & metabolism · 2026Article
- PCSK9 Inhibitors Reduce Oxidative Stress Biomarkers in Heterozygous Familial Hypercholesterolemia.Journal of cellular and molecular medicine · 2026Article
- Prooxidant-antioxidant balance as a predictor of mortality: findings from the Neyshabur Longitudinal study on Ageing.Biomarkers in medicine · 2025Article
- Hypercholesterolemia, oxidative stress, and low-grade inflammation: a potentially dangerous scenario to blood-brain barrier.Metabolic brain disease · 2025Review
- The Dual Role of Oxidative Stress in Atherosclerosis and Coronary Artery Disease: Pathological Mechanisms and Diagnostic Potential.Antioxidants (Basel, Switzerland) · 2025Review
- Untargeted metabolomics reveals distinct biomarkers and metabolic alterations in familial and non-genetic hypercholesterolemia in Saudi patients.Frontiers in medicine · 2025Article
- Profiling of differentially expressed MicroRNAs in familial hypercholesterolemia via direct hybridization.Non-coding RNA research · 2024Article
- Lipoprotein(a) is associated with DNA damage in patients with heterozygous familial hypercholesterolemia.Scientific reports · 2024Article
- iPSC-Derived Endothelial Cells Reveal LDLR Dysfunction and Dysregulated Gene Expression Profiles in Familial Hypercholesterolemia.International journal of molecular sciences · 2024Article
- Evaluation of miRNA-27a/b expression in patients with familial hypercholesterolemia.Archives of medical science : AMS · 2024Article
- Decreased Serum Stromal Cell-Derived Factor-1 in Patients with Familial Hypercholesterolemia and Its Strong Correlation with Lipoprotein Subfractions.International journal of molecular sciences · 2023Article
- Investigating the relationship between the VNTR variant of the interleukin-1 receptor antagonist gene and coronary in-stent restenosis.Molecular biology reports · 2023Article
- Review
- Capacity of HDL to Efflux Cellular Cholesterol from Lipid-Loaded Macrophages Is Reduced in Patients with Familial Hypercholesterolemia.Metabolites · 2023Article
- Oxidative Stress Parameters as Biomarkers of Cardiovascular Disease towards the Development and Progression.Antioxidants (Basel, Switzerland) · 2022Review
- Diabetes and Familial Hypercholesterolemia: Interplay between Lipid and Glucose Metabolism.Nutrients · 2022Review
- Association between Oxidative Burden and Restenosis: A Case-Control Study.Oxidative medicine and cellular longevity · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundFamilial hypercholesterolemia (FH) is an autosomal dominant genetic disorder characterizied by elevated levels of circulating low-density lipoprotein cholesterol (LDL-C) which is an important source of substrates to be oxidized by different oxidative agents. Subsequently, the oxidized LDLs (oxLDLs) induce further oxidative reactions in FH patients, which contributes to the development of atherosclerosis and advanced cardiovascular events in these patients. This study aimed to investigate the association of oxidant/antioxidant markers with FH.
methodsThis case-control study comprised 18 HoFH, 18 HeFH, and 20 healthy subjects. Oxidant/antioxidant markers including MDA, MPO, thiol, nitric oxide (NO), myeloperoxidase (MPO), glutathione peroxidase (GPx), SOD, and CAT were assessed by colorimetric methods. Prooxidant-antioxidant balance was also measured by pro-oxidant antioxidant balance (PAB) assay.
resultsThe levels of MDA (
conclusionSeveral oxidant/antioxidant differences were found between FH patients and healthy individuals as well as between HoFH and HeFH patients. These differences might be strongly dependent on plasma LDL-C levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.